Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design ; volume:21 ; number:1 ; day:8 ; month:6 ; year:2020 ; pages:1-13 ; date:12.2020
Trials ; 21, Heft 1 (8.6.2020), 1-13, 12.2020
- Creator
-
Nasib, Lyliana G.
Sommer, Iris E.
Winter - van Rossum, Inge
Vries, Jacqueline de
Gangadin, Shiral S.
Oomen, Priscilla P.
Judge, Gurmeet
Blom, Renske E.
Luykx, Jurjen J.
Beveren, Nico J. M. van
Veen, Natalie D.
Kroken, Rune A.
Johnsen, Erik L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13063-020-04365-4
- URN
-
urn:nbn:de:101:1-2020081920000305305949
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nasib, Lyliana G.
- Sommer, Iris E.
- Winter - van Rossum, Inge
- Vries, Jacqueline de
- Gangadin, Shiral S.
- Oomen, Priscilla P.
- Judge, Gurmeet
- Blom, Renske E.
- Luykx, Jurjen J.
- Beveren, Nico J. M. van
- Veen, Natalie D.
- Kroken, Rune A.
- Johnsen, Erik L.
- SpringerLink (Online service)
Other Objects (12)
Evaluating differential developmental trajectories to adolescent-onset mood and psychotic disorders
Aqueous photocatalytic oxidation of prednisolone
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial
Correction: Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial
Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease
Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration
Randomized controlled trial of pulse methyl prednisolone × placebo in treatment of pulmonary involvement associated with severe leptospirosis. [ISRCTN74625030]
Symptomatic care of late-onset Alexander disease presenting with area postrema-like syndrome with prednisolone; a case report
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders
Psychotic and schizotypal symptoms in non-psychotic patients with obsessive-compulsive disorder
Behavioral problems in psychotic, clinically high-risk, and non-psychotic adolescent patients
Prediction of Prednisolone Dose Correction Using Machine Learning
Evaluating differential developmental trajectories to adolescent-onset mood and psychotic disorders
Aqueous photocatalytic oxidation of prednisolone
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial
Correction: Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial
Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease
Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration
Randomized controlled trial of pulse methyl prednisolone × placebo in treatment of pulmonary involvement associated with severe leptospirosis. [ISRCTN74625030]
Symptomatic care of late-onset Alexander disease presenting with area postrema-like syndrome with prednisolone; a case report
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders
Psychotic and schizotypal symptoms in non-psychotic patients with obsessive-compulsive disorder
Behavioral problems in psychotic, clinically high-risk, and non-psychotic adolescent patients
Prediction of Prednisolone Dose Correction Using Machine Learning
Evaluating differential developmental trajectories to adolescent-onset mood and psychotic disorders
Aqueous photocatalytic oxidation of prednisolone
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial
Correction: Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial
Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease
Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration
Randomized controlled trial of pulse methyl prednisolone × placebo in treatment of pulmonary involvement associated with severe leptospirosis. [ISRCTN74625030]
Symptomatic care of late-onset Alexander disease presenting with area postrema-like syndrome with prednisolone; a case report
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders
Psychotic and schizotypal symptoms in non-psychotic patients with obsessive-compulsive disorder
Behavioral problems in psychotic, clinically high-risk, and non-psychotic adolescent patients